FY 2025 Restated (unaudited) Agfa-Gevaert Group
New Reporting Structure (since Q1 2026)
1
Agfa-Gevaert Group: Profit & Loss
in million euro | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | FY '25 |
Sales | 242 | 281 | 257 | 306 | 1086 |
Gross Profit* | 74 | 85 | 70 | 101 | 331 |
Operational expenses* | -81 | -81 | -73 | -72 | -307 |
Adj. EBITDA** | 2 | 13 | 5 | 39 | 59 |
Adj. EBIT** | -7 | 5 | -4 | 29 | 23 |
* Before restructuring and non-recurring items
2
* before adjustments and restructuring expenses
** Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to 'Results from operating activities'(EBIT)/EBITDA
HealthCare IT: Profit & Loss
in million euro | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | FY '25 |
Sales | 57 | 61 | 50 | 64 | 232 |
Gross Profit* | 27 | 30 | 22 | 35 | 115 |
Operational expenses* | -24 | -23 | -22 | -20 | -89 |
Adj. EBITDA** | 5.0 | 8.9 | 2.1 | 17.6 | 33.5 |
Adj. EBIT** | 3.2 | 7.2 | 0.3 | 15.2 | 26.0 |
3
* before adjustments and restructuring expenses
** Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to 'Results from operating activities'(EBIT)/EBITDA
Industrial Solutions: Profit & Loss
in million euro R = restated (unaudited) | Q1 '25R | Q2 '25R | Q3 '25R | Q4 '25R | FY '25R |
Sales | 43 | 54 | 53 | 73 | 223 |
Gross Profit* | 17 | 22 | 22 | 32 | 92 |
Operational expenses* | -22 | -21 | -19 | -20 | -82 |
Adj. EBITDA** | -2.1 | 3.7 | 5.9 | 15.3 | 22.8 |
Adj. EBIT** | -5.1 | 0.6 | 2.9 | 11.7 | 10.2 |
4
* before adjustments and restructuring expenses
** Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to 'Results from operating activities'(EBIT)/EBITDA
Key figures Profit & Loss Incl. IFRS 16
* Before restructuring and non-recurring items
5
Imaging and Chemicals: Profit & Loss
in million euro R = restated (unaudited) | Q1 '25R | Q2 '25R | Q3 '25R | Q4 '25R | FY '25R |
Sales | 142 | 167 | 154 | 169 | 631 |
Gross Profit* | 30 | 33 | 25 | 35 | 123 |
Operational expenses* | -32 | -32 | -29 | -31 | -123 |
Adj. EBITDA** | 2.6 | 3.7 | 0.4 | 8.5 | 15.1 |
Adj. EBIT** | -1.8 | 0.2 | -3.6 | 4.8 | -0.5 |
* before adjustments and restructuring expenses
** Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to 'Results from operating activities'(EBIT)/EBITDA
Corporate and Unassigned: Profit & Loss
in million euro | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | FY '25 |
Sales | 0 | 0 | 0 | 0 | 0 |
Gross Profit* | 0 | 1 | 0 | -1 | 0 |
Operational expenses* | -4 | -4 | -4 | -2 | -13 |
Adj. EBITDA** | -3.4 | -3.0 | -3.2 | -2.5 | -12.2 |
Adj. EBIT** | -3.4 | -3.1 | -3.3 | -2.6 | -12.3 |
* Before restructuring and non-recurring items
6
* before adjustments and restructuring expenses
** Adjusted EBIT/EBITDA with the deduction of adjustments and restructuring expenses reconciles to 'Results from operating activities'(EBIT)/EBITDA